Capital Investment Advisors LLC Cuts Stake in iShares Biotechnology ETF (NASDAQ:IBB)

Capital Investment Advisors LLC lowered its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 4.4% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 10,350 shares of the financial services provider’s stock after selling 472 shares during the period. Capital Investment Advisors LLC’s holdings in iShares Biotechnology ETF were worth $1,507,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Future Financial Wealth Managment LLC purchased a new stake in shares of iShares Biotechnology ETF during the first quarter worth about $27,000. Bbjs Financial Advisors LLC purchased a new stake in shares of iShares Biotechnology ETF during the second quarter worth about $31,000. Mather Group LLC. purchased a new stake in shares of iShares Biotechnology ETF during the first quarter worth about $57,000. Chris Bulman Inc purchased a new stake in shares of iShares Biotechnology ETF during the second quarter worth about $64,000. Finally, BNP Paribas acquired a new stake in shares of iShares Biotechnology ETF during the first quarter worth about $69,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of NASDAQ:IBB opened at $145.91 on Monday. iShares Biotechnology ETF has a 12-month low of $111.83 and a 12-month high of $150.57. The business has a 50 day moving average of $145.65 and a two-hundred day moving average of $139.69.

iShares Biotechnology ETF Announces Dividend

The firm also recently disclosed a dividend, which was paid on Monday, September 30th. Stockholders of record on Wednesday, September 25th were given a $0.2005 dividend. The ex-dividend date of this dividend was Wednesday, September 25th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.